Abstract:IUdR incorporation into cellular DNA enhances radiation induced DNA damage and impairs repair pathways. IUdR has been explored as a clinical radiation sensitizer in Phase I and II clinical trials of sarcomas and gliomas, showing clinical activity. A major barrier to acceptance of this therapy has been the poor pharmacokinetic (PK) profile of IUdR which has a blood plasma half-life of less than 10 minutes. Continuous IV infusion of IUdR has been used to achieve clinically relevant DNA incorporation into tumor cells, but technical limitations of delivery and acute toxicities in rapidly proliferating normal tissues presented barriers to advancing this approach. To improve the PK profile of IUdR, a prodrug strategy has been employed leading to the development of ropidoxuridine (IPdR), which improved the PK profile, demonstrated oral bioavailability of the active metabolite IUdR, showed less normal tissue toxicity, and provided tumor radiation sensitization. IPdR plus XRT has been tested in Phase 0 and Phase 1 clinical trials and a phase II trial is proposed for glioblastoma treatment. We report here a second approach to improve the PK profile of orally administered IUdR by combining these iodinated thymidine analogs with the metabolism inhibitor, Tipiracil (TPI) which inhibits thymidine phosphorylase, the primary enzyme responsible for irreversible IUdR degradation, and is currently used in the FDA approved combination drug Lonsurf. Oral co-administration of IUdR and TPI in rats dramatically improved the PK profile of IUdR, increasing the half-life of the compound to 1.5 hours and boosting the maximum plasma concentration by approximately 8-fold. We studied the effects of Tipiracil on the metabolism of IUdR by varying the molecular ratio of IUdR/TPI from 2:1 up to a ratio of 10:1 and discovered that the plasma concentration of IUdR plateaued between a ratio of 5:1 and 10:1. This new combination therapy of IUdR/TPI yields a PK profile of IUdR that is relevant to clinical treatment in combination with RT and offers to expand potential clinical radiation sensitizer applications. Citation Format: Scott Grindrod, Alfredo Velana, Tyvin Rich, Mira Jung, Dalong Pang, Anatoly Dritschilo. Enhanced DNA damage and disruption of repair by iodinated thymidine analogues with Tipiracil for clinical radiation sensitization [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr A005.

Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence

MHY1485 enhances X-irradiation-induced apoptosis and senescence in tumor cells

Upregulation of EID3 Sensitizes Breast Cancer Cells to Ionizing Radiation-Induced Cellular Senescence.

Abstract A005: Enhanced DNA damage and disruption of repair by iodinated thymidine analogues with Tipiracil for clinical radiation sensitization

Two Strategies for the Development of Mitochondrion-Targeted Small Molecule Radiation Damage Mitigators

MHY1485 potentiates immunogenic cell death induction and anti-cancer immunity following irradiation

MicroRNA regulation of ionizing radiation-induced premature senescence

2-Methoxyestradiol Enhances Radiosensitivity in Radioresistant Melanoma MDA-MB-435R Cells by Regulating Glycolysis Via HIF-1α/PDK1 Axis

Ionizing Radiation Triggers Mitophagy to Enhance DNA Damage in Cancer Cells.

Ionizing Radiation Upregulates Glutamine Metabolism and Induces Cell Death via Accumulation of Reactive Oxygen Species

Radiosensitization by Irinotecan is Attributed to G2/M Phase Arrest, Followed by Enhanced Apoptosis, Probably Through the ATM/Chk/Cdc25C/Cdc2 Pathway in P53-Mutant Colorectal Cancer Cells.

Diisopropylamine Dichloroacetate Enhances Radiosensitization in Esophageal Squamous Cell Carcinoma by Increasing Mitochondria-Derived Reactive Oxygen Species Levels.

Transfection of Human Tumour Cells with Mre11 Sirna and the Increase in Radiation Sensitivity and the Reduction in Heat-Induced Radiosensitization

Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235

Radiosensitization of PC3 Prostate Cancer Cells by 5-Thiocyanato-2'-deoxyuridine

Ubenimex Enhances the Radiosensitivity of Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death

Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells.

Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death

Diosmetin Enhances the Sensitivity of Radiotherapy by Suppressing Homologous Recombination in Endometrial Cancer.

Comparable radiation sensitivity in p53 wild-type and p53 deficient tumor cells associated with different cell death modalities

Polydatin Increases Radiosensitivity by Inducing Apoptosis of Stem Cells in Colorectal Cancer.